DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Invest...
January 07 2017 - 6:00AM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Northern
District of California on behalf of purchasers of Dynavax
Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the
“Company”) common shares during the period between March 10, 2014
and November 11, 2016, inclusive (the “Class Period”). Investors
who wish to become proactively involved in the litigation have
until January 17, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Dynavax common shares during the Class Period.
Members of the Class will be represented by the lead plaintiff and
counsel chosen by the lead plaintiff. No class has yet been
certified in the above action.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that there were
significant adverse events associated with Dynavax’s HEPLISAV-B
product, including an imbalance in the number of cardiac events
during use and a commercial product launch of HEPLISAV-B was less
imminent than Dynavax had led investors to believe.
According to the complaint, following a November 14,
2016 announcement that the Company had received a complete
response letter from the U.S. Food and Drug Administration
requesting additional information on the Company’s HEPLISAV-B
product, including clarification regarding specific adverse events
of special interest, a numerical imbalance in a small number of
cardiac events in a single study, new analyses of the integrated
safety data base across different time periods, and post-marketing
commitments, the value of Dynavax shares declined
significantly.
If you have suffered a loss in excess of $100,000 from
investment in Dynavax common shares purchased on or after March 10,
2014 and held through the revelation of negative information during
and/or at the end of the Class Period and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Brower Piven also encourages anyone with information
regarding the Company’s conduct during the period in question to
contact the firm, including whistleblowers, former employees,
shareholders and others.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170107005030/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024